Hillstream BioPharma (HILS) Competitors $1.15 +0.09 (+8.49%) As of 04/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock HILS vs. VIRI, IMUX, GALT, TELO, ANIX, ATOS, CLYM, PLRX, VERU, and ZNTLShould you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Virios Therapeutics (VIRI), Immunic (IMUX), Galectin Therapeutics (GALT), Telomir Pharmaceuticals (TELO), Anixa Biosciences (ANIX), Atossa Therapeutics (ATOS), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Veru (VERU), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry. Hillstream BioPharma vs. Virios Therapeutics Immunic Galectin Therapeutics Telomir Pharmaceuticals Anixa Biosciences Atossa Therapeutics Climb Bio Pliant Therapeutics Veru Zentalis Pharmaceuticals Virios Therapeutics (NASDAQ:VIRI) and Hillstream BioPharma (NASDAQ:HILS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings. Does the media favor VIRI or HILS? In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled Hillstream BioPharma'saverage media sentiment score. Company Overall Sentiment Virios Therapeutics Neutral Hillstream BioPharma Neutral Do analysts prefer VIRI or HILS? Virios Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 0.33%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Virios Therapeutics is more favorable than Hillstream BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Hillstream BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, VIRI or HILS? Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Hillstream BioPharma has a beta of 3.08, indicating that its stock price is 208% more volatile than the S&P 500. Is VIRI or HILS more profitable? Virios Therapeutics' return on equity of -130.33% beat Hillstream BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Hillstream BioPharma N/A -188.44%-149.61% Which has higher earnings & valuation, VIRI or HILS? Virios Therapeutics is trading at a lower price-to-earnings ratio than Hillstream BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-11.07Hillstream BioPharmaN/AN/A-$8.47M-$0.72-1.60 Do insiders and institutionals hold more shares of VIRI or HILS? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 13.4% of Hillstream BioPharma shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 30.2% of Hillstream BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer VIRI or HILS? Virios Therapeutics received 2 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Hillstream BioPharmaOutperform Votes150.00% Underperform Votes150.00% SummaryVirios Therapeutics beats Hillstream BioPharma on 8 of the 12 factors compared between the two stocks. Remove Ads Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HILS vs. The Competition Export to ExcelMetricHillstream BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.24M$6.35B$5.35B$7.58BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-1.606.7721.7617.79Price / SalesN/A229.14376.0394.59Price / CashN/A65.6738.1534.64Price / Book2.405.886.443.99Net Income-$8.47M$141.32M$3.20B$247.24M7 Day Performance-1.71%8.32%6.16%6.12%1 Month Performance-20.69%-12.93%-8.82%-7.11%1 Year Performance398.92%-12.47%9.66%-0.85% Hillstream BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HILSHillstream BioPharmaN/A$1.15+8.5%N/A+199.0%$20.24MN/A-1.601Gap UpVIRIVirios TherapeuticsN/A$4.25+1.7%$3.00-29.4%+483.5%$81.85MN/A-15.745Gap UpIMUXImmunic2.7003 of 5 stars$0.90-4.8%$13.20+1,374.9%-36.2%$80.69MN/A-0.7370GALTGalectin Therapeutics1.4896 of 5 stars$1.27-4.2%$11.00+766.1%-66.2%$80.24MN/A-1.749Gap DownTELOTelomir Pharmaceuticals2.0737 of 5 stars$2.58-6.9%$15.00+481.4%-69.6%$76.79MN/A-4.451Gap UpHigh Trading VolumeANIXAnixa Biosciences2.904 of 5 stars$2.38-4.4%$9.00+278.2%-16.4%$76.63M$210,000.00-6.105Gap DownATOSAtossa Therapeutics1.8944 of 5 stars$0.59-8.7%$7.00+1,084.2%-62.0%$76.35MN/A-2.698CLYMClimb Bio3.1752 of 5 stars$1.13-10.3%$10.00+785.0%N/A$76.25MN/A-0.539Gap DownPLRXPliant Therapeutics4.224 of 5 stars$1.23-2.0%$13.31+986.7%-90.0%$75.01M$1.58M-0.3790Gap DownVERUVeru2.0774 of 5 stars$0.51-10.1%$4.33+745.7%-64.1%$75.01M$16.89M-1.97230Positive NewsZNTLZentalis Pharmaceuticals2.4173 of 5 stars$1.04-10.3%$8.24+692.7%-90.9%$74.68M$67.43M-0.42160Gap Up Remove Ads Related Companies and Tools Related Companies VIRI Competitors IMUX Competitors GALT Competitors TELO Competitors ANIX Competitors ATOS Competitors CLYM Competitors PLRX Competitors VERU Competitors ZNTL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HILS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HILS Stock Free HILS Stock Alerts